ImmunoGen is focused on changing lives, by using our proven ADC technology to develop novel therapies to provide significant benefits to people with cancer.
ImmunoGen is a recognized leader in the field of ADCs. Our technology is used in Roche’s Kadcyla® (ado-trastuzumab emtansine) which is making a difference for patients today. Numerous leading healthcare companies have licensed limited rights to use our technology to develop ADC therapies, including Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda.
We are also using our proven technology and expertise to develop novel ADCs for our own product pipeline. We believe successfully advancing our own significant ADC therapies will make the greatest difference for patients with the relevant cancers while also generating the most value for our shareholders.
We also continue to invest to maintain our leadership in the emerging, high potential field of ADCs, with 765 issued patents and 749 pending patent applications worldwide as of mid-2016.
Kadcyla® is a registered trademark of Genentech, Inc., a member of the Roche Group.